Tenofovir Disoproxil CAS 201341-05-1 C19H30N5O10P

Product Description:

Product Name: Tenofovir disoproxil CAS NO: 201341-05-1

Synonyms:

(R)-(((((1-(6-AMino-9H-purin-9-yl)propan-2-yl)oxy)Methyl)phosphoryl)bis(oxy))bis(Methylene) diisopropyl dicarbonate;

2,4,6,8-Tetraoxa-5-phosphanonanedioicacid,5-[[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-,1,9-bis(1-Methylethyl) ester, 5-oxide;

TenofivirDisoproxilFumarate;

Chemical & Physical Properties:

Appearance: Solid

Assay :≥99.0%

Density: 1.45g/cm3

Boiling Point: 642.7℃ at 760mmHg

Flash Point: 342.5℃

Refractive Index: 1.578

Vapor Pressure: 2.06E-16mmHg at 25℃

Tenofovir diproxil fumarate, a water-soluble diester precursor of the active ingredient tenofovir, was developed by Gillett, Inc. In 2008, the FDA approved tenofovir dioxin for the treatment of chronic hepatitis B. In 2014, it was approved by CFDA for the treatment of chronic hepatitis B in adults and Chemicalbook children ≥12 years old (weight ≥35kg). Tenofovir dioxin is a highly potent gene barrier drug with high drug resistance. It is recommended by the international authoritative guidelines for treatment of liver disease for the first-line antiviral treatment of chronic hepatitis B, with excellent clinical efficacy, good tolerance and sufficient evidence. Used in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infection.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.